Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma.

导出 LinkOut

翻译打印收藏纠错

第一作者： Can,Lu

第一单位： Department of Pathology, Xiangya Hospital, Central South University, Changsha, China.

作者： Can,Lu ^[1] ; Xi,Chen ^[2] ; Yuanliang,Yan ^[2] ; Xinxin,Ren ^[3] ; Xiang,Wang ^[2] ; Bi,Peng ^[1] ; Yuan,Cai ^[1] ; Qiuju,Liang ^[2] ; Zhijie,Xu ^[1] ; Jinwu,Peng ^[4]

作者单位： Department of Pathology, Xiangya Hospital, Central South University, Changsha, China. ^[1] Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China. ^[2] Key Laboratory of Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, China. ^[3] Department of Pathology, Xiangya Changde Hospital, Changde, China. ^[4] National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. ^[5]

关键词 ADARB1 akt glioblastoma immune temozolomide

DOI 10.3389/fphar.2022.768743

PMID 35177985

发布时间 2022-02-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2022年13卷

768743页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除